The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
Advertisement
http://www.reportlinker.com/p0168104/The-Future-of-Orphan-Diseases-Therapeutics---Market-Forecasts-to-2015-Pipeline-Analysis-and-Reimbursement.html
Advertisement
Summary
The author has released its latest research "The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement" The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global orphan diseases therapeutics market. The report analyzes the markets for orphan diseases therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, and price are forecast until 2015 for the key geographies as well as select therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
Scope
The scope of this report includes:
Reasons to buy
The report will enhance your decision making capability. It will allow you to
Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 The Global Orphan Diseases Therapeutics Market is Forecast to Show Increased Growth Due to Increased Approval of Orphan Drugs
2.2 Orphan Drug Licensing is Growing at a Faster Rate Owing to High Market Potential
2.3 High Unmet Needs in the Boosts the R&D Scenario in Orphan Diseases Therapeutics Market
3 Global Orphan Diseases Market: Introduction
3.1 Disease Overview
3.1.1 The United States
3.1.2 Europe
3.1.3 Japan
3.2 GBI Research Report Guidance
3.3 Market Overview
4 Global Orphan Diseases Therapeutics Market: Market Characterization
4.1 Market Forecasts
4.2 Orphan Drugs by Disease Sectors
4.3 Usage Patterns
4.3.1 Diseased Population
4.3.2 Treatment Seeking Population
4.3.3 Diagnosis Population
4.3.4 Prescription Population
4.3.5 Therapeutic Usage Patterns
4.4 Geographical Distribution
4.4.1 Market Drivers
4.4.1.1 Increasing Approvals of Orphan Drugs and Orphan Drug Designations
4.4.1.2 Increase in awareness levels of disease progression and etiology
4.4.1.3 Federal Support for Research and Development of Orphan Drugs
4.4.2 Market Restraints
4.4.2.1 Lack of access to correct diagnosis
4.4.2.2 High cost of the few existing drugs and care
4.4.2.3 Delay in Diagnosis and Misdiagnosis
4.5 Key Market Trends
4.5.1 Increase Federal Funding
4.5.2 Product Pipeline
4.5.3 Regulatory trends - Current Pricing and Reimbursement Scenario
4.5.3.1 Innovative risk-sharing agreements have emerged as tools to provide market access
4.5.3.2 Excessive Pricing of Orphan Drugs by the Pharma Companies Demands Measures for Greater Price Control
4.5.3.3 Pricing and Reimbursement Issues for Orphan Drugs - Excessive Prices of Orphan Drugs Increasing Financial Pressures on Government
4.5.3.4 Exploiting Orphan Drug Act; Maximizing Revenues
4.5.3.5 Ovation's Indocin and Questcor's H.P. Acthar Gel
4.5.3.6 Pricing an Orphan Drug
4.5.3.7 Price Control Measures
4.5.3.8 Global Approach for Orphan Drug Development
4.5.3.9 Introducing Sales Ceiling and Flexible Market Exclusivity
4.5.3.10 Price Revisions
4.5.3.11 GSK's Retrovir (zidovudine)
4.5.3.12 Amgen's Epogen (erythropoietin)
4.5.3.13 Conclusion
5 Global Fabry Disease Therapeutics Market
5.1 Market Overview
5.2 Market Forecasts
5.3 Average Cost of Therapy
5.4 Usage Patterns
5.4.1 Diseased Population
5.4.2 Treatment Seeking Population
5.4.3 Diagnosis Population
5.4.4 Prescription Population
5.4.5 Therapeutic Usage Patterns
5.5 Product Analysis
5.5.1 Fabryzyme
5.5.2 Replagal
5.6 Drug Pipeline Analysis
6 Global Pompe Disease Therapeutics Market
6.1 Market Overview
6.2 Market Forecasts
6.3 Average Cost of Therapy
6.4 Usage Patterns
6.4.1 Diseased Population
6.4.2 Treatment Seeking Population
6.4.3 Diagnosis Population
6.4.4 Prescription Population
6.4.5 Therapeutic Usage Patterns
6.5 Product Analysis
6.5.1 Myozyme
6.5.1.1 Sales of Myozyme
6.6 Pipeline
7 Global Mucopolysaccharidosis VI Disease Therapeutics Market
7.1 Market Overview
7.2 Market Forecasts
7.3 Average Cost of Therapy
7.4 Usage Patterns
7.4.1 Diseased Population
7.4.2 Treatment Seeking Population
7.4.3 Diagnosis Population
7.4.4 Prescription Population
7.4.5 Therapeutic Usage Patterns
7.5 Product Analysis
7.5.1 Naglazyme
7.5.1.1 Sales of Naglazyme
8 The US Orphan Diseases Therapeutics Market
8.1 Market Overview
8.2 Market Forecasts
8.3 Usage Patterns
8.3.1 Diseased Population
8.3.2 Treatment Seeking Population
8.3.3 Diagnosis Population
8.3.4 Prescription Population
8.3.5 Therapeutic Usage Patterns
9 Europe Orphan Diseases Therapeutics Market
9.1 Market Overview
9.2 Market Forecasts
9.3 Usage Patterns
9.3.1 Diseased Population
9.3.2 Treatment Seeking Population
9.3.3 Diagnosis Population
9.3.4 Prescription Population
9.3.5 Therapeutic Usage Patterns
10 Japan Orphan Diseases Therapeutics Market
10.1 Market Overview
10.2 Market Forecasts
10.3 Usage Patterns
10.3.1 Diseased Population
10.3.2 Treatment Seeking Population
10.3.3 Diagnosis Population
10.3.4 Prescription Population
10.3.5 Therapeutic Usage Patterns
11 Global Orphan Diseases Therapeutics Market: Competitive Landscape
11.1 Overview
11.2 Competitor Profiling
11.2.1 Genzyme Corporation
11.2.1.1 Strengths - Broad Product Base and Orphan Drug Status Strengthens Company's positioning
11.2.1.2 Cerezyme
11.2.1.3 Fabrazyme
11.2.2 Celgene Corporation
11.2.2.1 Strengths - Orphan Drugs Driving Revenues in a Competition Free Environment
11.2.3 Actelion Pharmaceuticals
11.2.4 Shire Pharmaceuticals
11.2.5 AstraZeneca
11.2.6 Boehringer Ingelheim
11.2.7 Bristol-Myers Squibb
11.2.8 GlaxoSmithKline (GSK)
11.2.9 Novartis
11.2.10 Pfizer
11.2.11 Eli Lilly
11.2.12 Sanofi Aventis
11.2.13 UCB Pharma
11.2.14 Wyeth
12 Pipeline Analysis
12.1 Autoimmune Disorders
12.1.1 Cellcept
12.1.2 Pirfenidone
12.1.3 Rituxan
12.2 Genetic Disorders
12.2.1 Denufosol tetrasodium inhalation solution(INS37217)
12.2.2 Bronchitol(Mannitol)
12.2.3 Catena (Idebenone)
12.3 Infectious Diseases
12.3.1 XP-28 (xepol)
12.4 Neurology
12.4.1 Cladribine
12.4.2 Clazosentan (Pivlaz®)
12.5 Respiratory Disorders
12.6 Transplantation
12.7 Cardiovascular Disorders
12.7.1 ISIS 301012(Mipomersen sodium)
12.8 Cancer
12.8.1 Avastin
12.8.2 Enzastaurin
12.8.3 Patupilone
12.8.4 Zactima
12.8.5 Genasense
12.8.6 Ipilimumab (MDX-010, MDX-101)
12.9 Blood Cancer
12.10 Skin Cancer
12.11 Other Disorders
13 Global Orphan Diseases Therapeutics Market: Strategic Consolidations
13.1 Mergers and Acquisitions
13.1.1 Genzyme Corp. and Bioenvision, Inc.
13.1.2 ViroPharma and Lev Pharmaceuticals
13.1.3 Biovitrum and Swedish Orphan
13.1.4 Shire plc and Zymenex A/s
13.2 Licensing Agreements
13.2.1 Overview
13.2.2 Drug Discovery & Preclinical
13.2.2.1 DX-88
13.2.2.2 ThermoDox
13.2.3 Phase I
13.2.3.1 Xenazine
13.2.3.2 BL-1040
13.2.3.3 SB1518
13.2.4 Phase II
13.2.4.1 Treanda
13.2.4.2 Onalta
13.2.4.3 ARQ 197
13.2.4.4 TMC-207
13.2.5 Phase III
13.2.5.1 Glufosfamide
13.2.5.2 Allovectin-7
13.2.5.3 Trizytek
13.2.5.4 OrBec
13.2.5.5 Riquent
13.2.5.6 Xiaflex
13.2.5.7 Eurartesim
13.2.5.8 Gabapentin GR
13.2.6 Approved
13.2.6.1 Cyanokit
13.2.6.2 Fomepizole
13.2.6.3 Xenazine
13.2.6.4 fludarabine
13.2.6.5 Curosurf
13.2.6.6 Campath
13.2.6.7 Epoprostenol
13.2.6.8 Somatostatin-UCB
13.2.6.9 Chenix
13.2.6.10 Gliadel
13.2.6.11 Zevalin
13.2.6.12 Desmopressin Acetate
14 Appendix
14.1 Market Definitions
14.2 Key Support Data
14.3 List of Abbreviations
14.4 Research Methodology
14.4.1 Coverage
14.4.2 Secondary Research
14.4.3 Primary Research
14.4.4 Models
14.4.5 Forecasts
14.4.6 Expert Panels
14.5 Contact Us
14.6 Disclaimer
Table 1: Orphan Diseases Therapeutics Market: Definition and Incentives for Orphan Drugs, 2008
Table 2: Orphan Diseases Therapeutics Market: Orphan Diseases Prevalence, Europe, 2008
Table 3: Orphan Diseases Therapeutics Market, Global, Revenue Forecasts, 2000-2008
Table 4: Orphan Diseases Therapeutics Market, Global, Revenue Forecasts, 2008-2015
Table 5: Orphan Diseases Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008
Table 6: Orphan Diseases Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
Table 7: Orphan Diseases Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008
Table 8: Orphan Diseases Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
Table 9: Orphan Diseases Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008
Table 10: Orphan Diseases Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
Table 11: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2008
Table 12: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015
Table 13: Orphan Diseases Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2008
Table 14: Orphan Diseases Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015
Table 15: Orphan Diseases Therapeutics Market, Global, Market Drivers, 2009-2015
Figure 14: Orphan Diseases Therapeutics Market, Europe, Approved Orphan Drugs and Indications, 2008
Table 16: Orphan Diseases Therapeutics Market, Global, Market Restraints, 2009 - 2015
Table 17: Orphan Diseases Therapeutics Market, Definition and Incentives for Orphan Drugs, 2008
Figure 17: Orphan Diseases Therapeutics Market, Global, Prevalence and the Annual Cost of Therapy
Table 18: Fabry Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2008
Table 19: Fabry Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015
Table 20: Fabry Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2008
Table 21: Fabry Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015
Table 22: Fabry Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008
Table 23: Fabry Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
Table 24: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008
Table 25: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
Table 26: Fabry Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008
Table 27: Fabry Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
Table 28: Fabry Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2001-2008
Table 29: Fabry Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015
Table 30: Fabry Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
Table 31: Pompe Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2008
Table 32: Pompe Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015
Table 33: Pompe Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008
Table 34: Pompe Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
Table 35: Pompe Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008
Table 36: Pompe Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
Table 37: Pompe Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008
Table 38: Pompe Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
Table 39: Pompe Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015
Table 40: Pompe Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2008
Table 41: Pompe Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015
Table 42: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
Table 43: Pompe Disease Therapeutics Market, Global, Myozyme Sales, 2008
Table 44: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2015
Table 45: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015
Table 46: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008
Table 47: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
Table 48: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008
Table 49: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
Table 50: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008
Table 51: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
Table 52: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015
Table 53: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
Table 54: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Naglazyme Sales, 2008
Table 55: Orphan Diseases Therapeutics Market, The US, Revenue Forecasts ($m), 2000-2008
Table 56: Orphan Diseases Therapeutics Market, The US, Revenue Forecasts ($m), 2008-2015
Table 57: Orphan Diseases Therapeutics Market, The US, Forecasts for Diseased Population, 2000-2008
Table 58: Orphan Diseases Therapeutics Market, The US, Forecasts for Diseased Population, 2008-2015
Table 59: Orphan Diseases Therapeutics Market, The US, Forecasts for Treatment Seeking Population, 2000-2008
Table 60: Orphan Diseases Therapeutics Market, The US, Forecasts for Treatment Seeking Population, 2008-2015
Table 61: Orphan Diseases Therapeutics Market, The US, Forecasts for Diagnosis Population, 2000-2008
Table 62: Orphan Diseases Therapeutics Market, The US, Forecasts for Diagnosis Population, 2008-2015
Table 63: Orphan Diseases Therapeutics Market, The US, Forecasts for Prescription Population, 2000-2008
Table 64: Orphan Diseases Therapeutics Market, The US, Forecasts for Prescription Population, 2008-2015
Table 65: Orphan Diseases Therapeutics Market, The US, Forecasts for Therapeutic Usage Patterns, 2000-2008
Table 66: Orphan Diseases Therapeutics Market, The US, Forecasts for Therapeutic Usage Patterns, 2008-2015
Table 67: Orphan Diseases Therapeutics Market, Europe, Revenue Forecasts ($bn), 2000-2008
Table 68: Orphan Diseases Therapeutics Market, Global, Revenue Forecasts ($bn), 2008-2015
Table 69: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diseased Population, 2000-2008
Table 70: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diseased Population, 2008-2015
Table 71: Orphan Diseases Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2000-2008
Table 72: Orphan Diseases Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2008-2015
Table 73: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2000-2008
Table 74: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2008-2015
Table 75: Orphan Diseases Therapeutics Market, Europe, Forecasts for Prescription Population, 2000-2008
Table 76: Orphan Diseases Therapeutics Market, Europe, Forecasts for Prescription Population, 2008-2015
Table 77: Orphan Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2000-2015
Table 78: Orphan Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2000-2015
Table 79: Orphan Diseases Therapeutics Market, Japan, Revenue Forecasts ($m), 2000-2015
Table 80: Orphan Diseases Therapeutics Market, Japan, Revenue Forecasts ($m), 2002-2015
Table 81: Orphan Diseases Therapeutics Market, Japan, Forecasts for Diseased Population, 2000-2008
Table 82: Orphan Diseases Therapeutics Market, Japan, Forecasts for Diseased Population, 2008-2015
Table 83: Orphan Diseases Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2000-2008
Table 84: Orphan Diseases Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2008-2015
Table 85: Orphan Diseases Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2000-2008
Table 86: Orphan Diseases Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2008-2015
Table 87: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2008
Table 88: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015
Table 89: Orphan Diseases Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2000-2008
Table 90: Orphan Diseases Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2008-2015
Table 91: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Autoimmune Disorders, 2008
Table 92: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Genetic Disorders, 2008
Table 93: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Infectious Diseases, 2008
Table 94: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Neurology Disorders, 2008
Table 95: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Respiratory Disorders, 2008
Table 96: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Transplantation, 2008
Table 97: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Cardiovascular Disorders, 2008
Table 98: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Cancer, 2008
Table 99: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Blood Cancer, 2008
Table 100: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Skin Cancer, 2008
Table 101: Orphan Diseases Therapeutics Market, Global, Pipeline Analysis of Autoimmune Disorders, 2008
Table 102: Orphan Diseases Therapeutics Market, Global, Licensing Agreements for Drugs in the Discovery and Preclinical Stages, 2008
Table 103: Orphan Diseases Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I Stage, 2008
Table 104: Orphan Diseases Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II Stages, 2008
Table 105: Orphan Diseases Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III Stages, 2008
Table 106: Orphan Diseases Therapeutics Market, Global, Licensing Agreements for Drugs in the Approved Stages, 2008
List of Figures
Figure 1: Orphan Diseases Therapeutics Market, Global, Market Overview, 2008
Figure 2: Orphan Diseases Therapeutics Market, Global, Revenue Forecasts, 2000-2015
Figure 3: Orphan Diseases Therapeutics Market, The US, Orphan Drugs by Disease Sectors, 2008
Figure 4: Orphan Diseases Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015
Figure 5: Orphan Diseases Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015
Figure 6: Orphan Diseases Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015
Figure 7: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015
Figure 8: Orphan Diseases Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 9: Orphan Diseases Therapeutics Market, Global, Geographical Distribution of Revenues ($bn), 2000-2015
Figure 10: Orphan Diseases Therapeutics Market, Global, Geographical Comparison of Market Competition, 2008
Figure 11: Orphan Diseases Therapeutics Market, Global, Market Indicators, 2008
Figure 12: Orphan Diseases Therapeutics Market, The US, Approved Orphan Drugs, 20008-2009
Figure 13: Orphan Diseases Therapeutics Market, The US and Europe, Designated Orphan Drugs, 2004-2018
Figure 14: Orphan Diseases Therapeutics Market, Europe, Approved Orphan Drugs and Indications, 2008
Figure 15: Orphan Diseases Therapeutics Market, Global, Key Market Events, 2008-2015
Figure 16: Orphan Diseases Therapeutics Market, Global, Pricing of an Orphan Drug, 2008
Figure 17: Orphan Diseases Therapeutics Market, Global, Prevalence and the Annual Cost of Therapy
Figure 18: Orphan Diseases Therapeutics Market, Global, Price Control Measures on Orphan Drugs
Figure 19: Fabry Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2015
Figure 20: Fabry Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2015
Figure 21: Fabry Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015
Figure 22: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015
Figure 23: Fabry Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015
Figure 24: Fabry Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015
Figure 25: Fabry Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 26: Fabry Disease Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008
Figure 27: Fabry Disease Therapeutics Market, Global, Historical Revenues of Major Drugs ($m), 2006-2008
Figure 28: Pompe Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2015
Figure 29: Pompe Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015
Figure 30: Pompe Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015
Figure 31: Pompe Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015
Figure 32: Pompe Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015
Figure 33: Pompe Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015
Figure 34: Pompe Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 35: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2015
Figure 36: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015
Figure 37: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015
Figure 38: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015
Figure 39: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015
Figure 40: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015
Figure 41: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 42: Orphan Diseases Therapeutics Market, The US, Revenue Forecasts ($m), 2000-2015
Figure 43: Orphan Diseases Therapeutics Market, The US, Forecasts for Diseased Population, 2000-2015
Figure 44: Orphan Diseases Therapeutics Market, The US, Forecasts for Treatment Seeking Population, 2000-2015
Figure 45: Orphan Diseases Therapeutics Market, The US, Forecasts for Diagnosis Population, 2000-2015
Figure 46: Orphan Diseases Therapeutics Market, The US, Forecasts for Prescription Population, 2000-2015
Figure 47: Orphan Diseases Therapeutics Market, The US, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 48: Orphan Diseases Therapeutics Market, Europe, Revenue Forecasts ($bn), 2000-2015
Figure 49: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diseased Population, 2000-2015
Figure 50: Orphan Diseases Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2000-2015
Figure 51: Orphan Diseases Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2000-2015
Figure 52: Orphan Diseases Therapeutics Market, Europe, Forecasts for Prescription Population, 2000-2015
Figure 53: Orphan Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 54: Orphan Diseases Therapeutics Market, Japan, Revenue Forecasts ($m), 2000-2015
Figure 55: Orphan Diseases Therapeutics Market, Japan, Forecasts for Diseased Population, 2000-2015
Figure 56: Orphan Diseases Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2000-2015
Figure 57: Orphan Disease Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2000-2015
Figure 58: Orphan Diseases Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015
Figure 59: Orphan Diseases Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 60: Orphan Diseases Therapeutics Market, The US, Orphan Drug Indications, 2000-2008
Figure 61: Orphan Diseases Therapeutics Market, Global, Sales Revenues of Orphan Drugs, 2008
Figure 62: Orphan Diseases Therapeutics Market, Global, Pipeline Split by Disease Sectors, 2008
Figure 63: Orphan Diseases Therapeutics Market, Global, Licensing Agreements Split by Disease Sectors, 2008
Figure 64: Orphan Diseases Therapeutics Market, Global, Licensing Agreements Split by Clinical Trial Phase, 2008
Figure 65: Orphan Diseases Therapeutics Market, Global, Licensing Agreements Split by Deal Size, 2008
Figure 66: GBI Research Methodology
Companies mentioned
Genzyme Corporation
Celgene Corporation
Actelion Pharmaceuticals
Shire Pharmaceuticals
AstraZeneca
Boehringer Ingelheim
Bristol-Myers Squibb
GlaxoSmithKline (GSK)
Novartis
Pfizer
Eli Lilly
Sanofi Aventis
UCB Pharma
To order this report:
Pharmaceutical Industry: The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
More Market Research Report
-- Annualized market data for the orphan diseases therapeutics market from 2000 to 2008, forecast forward to 2015 -- Analysis of the leading therapeutic segments. These include Fabry Disease, Pompe Disease and Mucopolysaccharidosis. -- Analysis of the orphan diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan -- Market characterization of the orphan diseases therapeutics market including market size, annual cost of therapy, and treatment usage patterns -- Key drivers and barriers that have a significant impact on the market -- Coverage of pipeline molecules in various phases of drug development -- Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Genzyme Corporation, Novartis AG, Celgene Corporation, Orphan Europe, Pfizer Inc, Actelion Pharmaceuticals and Shire Plc. -- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global orphan diseases therapeutics market
SOURCE Reportlinker
